Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MDCO: Medicines Company -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (9)	8/19/2001 1:35:01 AM
From: tuck	Read Replies (1) \| Respond to of 125

Trying to get through the history of AngioMax. Apparently it showed some superiority to heparin in acute settings, but the benefits didn't last. >>Cathet Cardiovasc Diagn. 1997 Nov;42(3):257-8 Pharmacologic prevention of acute ischemic complications of coronary angioplasty. Wheeldon N, Cumberland D. Cardiothoracic Unit, Northern General Hospital National Health Service Trust, Sheffield, United Kingdom. The risk of acute coronary occlusion following percutaneous transluminal coronary angioplasty (PTCA) has remained high despite the traditional use of heparin and aspirin. Interest has focused on newer strategies for preventing intracoronary thrombus formation, which is an important mechanism of abrupt vessel closure. Pretreatment with thrombolytic agents has failed vigorous testing in double-blind trials. Retrospective and observational studies have indicated that pretreatment with intravenous heparin is of benefit in patients with unstable symptoms, but prolonged infusion after angioplasty increases bleeding complications without improving outcomes. Subcutaneous heparin may be safer, but has not proved more effective. Oral dipyridamole has shown no advantage over aspirin, although there is evidence to suggest a benefit when given intravenously. Direct thrombin inhibitors (such as hirudin and hirulog) are associated with fewer early complications compared with heparin, but have yielded no apparent long-term benefit. The use of the antiplatelet drug ticlopidine is increasing, although long-term data are lacking. A great deal of recent interest has focused on newer antiplatelet agents, particularly the glycoprotein IIB/IIIa receptor inhibitor c7E3 Fab. In a large-scale trial, c7E3 significantly reduced the 30-day rate of mortality and cardiac events, and these benefits were maintained at 6 mo. This drug, unlike other antiplatelet agents, inhibits the final common pathway of platelet aggregation, which influences not only acute closure but has lasting effects for at least 6 mo. This may reflect a reduction in restenosis, although this remains to be proven. This article gives a brief overview of the pharmacologic agents available for the prophylaxis and treatment of acute ischemic complications of PTCA.<< snip An FDA panel failed to approve it the first go round, perhaps because of the above? But last December it got through for another indication. Still digging. The compound with all the letters and roman numerals is ReoPro (proabably I didn't have to tell you that). So they're going the combo route, with ReoPro & Integrilin, among others. Wondering if any of this crossed your radar. Based on your response, it doesn't look like it has. Guess I'll dig on for my own satisaction. Cheers, Tuck